UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000048442
Receipt number R000055205
Scientific Title The development of a midline abdominal wall incision closure technique to reduce the incidence of wound complications after elective gastroenterological surgery
Date of disclosure of the study information 2022/08/01
Last modified on 2024/01/23 12:39:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The development of a midline abdominal wall incision closure technique to reduce the incidence of wound complications after elective gastroenterological surgery

Acronym

The development of a midline abdominal wall incision closure technique to reduce the incidence of wound complications after elective gastroenterological surgery

Scientific Title

The development of a midline abdominal wall incision closure technique to reduce the incidence of wound complications after elective gastroenterological surgery

Scientific Title:Acronym

The development of a midline abdominal wall incision closure technique to reduce the incidence of wound complications after elective gastroenterological surgery

Region

Japan


Condition

Condition

The patients who undergo elective gastroenterological surgery with a class II (clean-contaminated) surgical wound

Classification by specialty

Gastrointestinal surgery Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The evaluation of the superiority of the combination of continuous sutures of fascia without peritoneum closure and continuous sutures of subcutaneous tissue over that of interrupted sutures for fascia together with peritoneum and interrupted sutures of subcutaneous tissue for reducing the incidence of wound complications of midline abdominal wall incision after elective gastroenterological surgery

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The incidence of postoperative wound complications, including wound bleeding, hematoma, surgical site infection, seroma and wound dehiscence within 30 days after surgery, and incisional hernia within 1 year after surgery

Key secondary outcomes

Duration of abdominal wall closure and wound pain seven days after surgery


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Midline abdominal wall incision closure with continuous sutures of fascia without peritoneum closure and continuous sutures of subcuticular tissue

Interventions/Control_2

Midline abdominal wall incision closure with interrupted sutures for fascia together with peritoneum and interrupted sutures of subcuticular tissue

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1 Scheduled to undergo elective surgery for esophagus, stomach, duodenum, jejunum, ileum, colorectal, pancreas, liver or biliary tract with a class II (clean-contaminated) surgical wound
2 Age >= 18 years old at the time of consent being obtained by non-blinded investigators.
3 Scheduled to undergo computed tomography one year after surgery
4 Written informed consent provided

Key exclusion criteria

1 Emergency surgery
2 Under 18 years old
3 A history of midline abdominal wall incision
4 A history of abdominal incisional hernia or fascial tear
5 Identification of bacterial infection in the surgical field or the use antibiotic therapy prior to the operation.
6 Presence of a contaminated abdominal cavity due to stoma, intestinal fistula or drainage tube.
7 Open wound management for prior operation.
8 Synchronous operation for more than two targeted organs.
9 Current immunotherapy (>= 40 mg of a corticosteroid per day or azathioprine)
10 Chemotherapy within 14 days prior to surgery
11 A history of radiotherapy of the abdomen
12 Pregnancy
13 Registered for another clinical trial
14 Conditions that make the patient unsuitable for inclusion according to the judgement of non-blinded investigators.

Target sample size

284


Research contact person

Name of lead principal investigator

1st name Toshiki
Middle name
Last name Rikiyama

Organization

Saitama Medical Center, Jichi Medical University

Division name

Department of Surgery

Zip code

330-8503

Address

1-847, Amanuma-cho, Omiya-ku, Saitama

TEL

0486472111

Email

trikiyama@jichi.ac.jp


Public contact

Name of contact person

1st name Yuki
Middle name
Last name Mizusawa

Organization

Saitama Medical Center, Jichi Medical University

Division name

Department of Surgery

Zip code

330-8503

Address

1-847, Amanuma-cho, Omiya-ku, Saitama

TEL

0486472111

Homepage URL


Email

yuki.afterdark@gmail.com


Sponsor or person

Institute

Saitama Medical Center, Jichi Medical University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Bioethics Committee for Clinical Research, Saitama Medical Center, Jichi Medical University

Address

1-847, Amanuma-cho, Omiya-ku, Saitama

Tel

0486472111

Email

s-suishin@jichi.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD

Yes

IPD sharing Plan description

Immediately after the publication of the primary results, de-identified individual participant data that underlie the results reported in the article(s) and other documents (study protocol and statistical analysis plan) will be available for any purpose, only if approved by the Bioethics Committee for Clinical Research, Saitama Medical Center, Jichi Medical University. Anyone who wishes to access the data should submit a proposal to s08.086sf@jichi.ac.jp. If approved, data requestors will need to sign a data access agreement. After that, the principal investigator will transfer the data and other documents to data requestors.


Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2022 Year 06 Month 23 Day

Date of IRB

2022 Year 06 Month 30 Day

Anticipated trial start date

2022 Year 08 Month 01 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 07 Month 23 Day

Last modified on

2024 Year 01 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055205


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name